Gaixotasun endokrinoak @page { } table { border-collapse:collapse; border-spacing:0; empty-cells:show } td, th { vertical-align:top; font-size:12pt;} h1, h2, h3, h4, h5, h6 { clear:both } ol, ul { margin:0; padding:0;} li { list-style: none; margin:0; padding:0;} <!-- "li span.odfLiEnd" - IE 7 issue--> li span. { clear: both; line-height:0; width:0; height:0; margin:0; padding:0; } span.footnodeNumber { padding-right:1em; } span.annotation_style_by_filter { font-size:95%; font-family:Arial; background-color:#fff000; margin:0; border:0; padding:0; } * { margin:0;} .gr1 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr10 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr11 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr12 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr13 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr14 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr15 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr16 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr17 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr18 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr19 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr2 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr20 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr21 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr22 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr23 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr24 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr25 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr26 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr27 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr28 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr29 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr3 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr30 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr31 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr32 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr33 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr34 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr35 { font-size:24pt; writing-mode:lr-tb; } .gr36 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .gr4 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr5 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr6 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr7 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr8 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr9 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .P1 { font-size:14pt; } .P10 { margin-left:0cm; margin-right:0cm; margin-top:0.44cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P11 { margin-left:0cm; margin-right:0cm; margin-top:0.617cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P12 { margin-left:0cm; margin-right:0cm; margin-top:0.635cm; margin-bottom:0cm; line-height:80%; text-align:justify ! important; text-indent:0cm; } .P13 { margin-left:0cm; margin-right:0cm; margin-top:0.74cm; margin-bottom:0cm; text-indent:0cm; } .P14 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P15 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P16 { margin-left:2.063cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:-0.793cm; } .P17 { text-align:center ! important; writing-mode:lr-tb; } .P18 { margin-left:0.952cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-align:center ! important; text-indent:-0.952cm; } .P19 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:0cm; } .P2 { text-align:right ! important; font-size:14pt; } .P20 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P21 { margin-left:1.834cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:90%; text-indent:-1.834cm; } .P22 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P23 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P24 { margin-left:0cm; margin-right:0cm; margin-top:0.493cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P25 { margin-left:0cm; margin-right:0cm; margin-top:0.423cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P26 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P27 { margin-left:0.952cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; line-height:90%; text-indent:-0.952cm; } .P28 { margin-left:2.063cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:90%; text-indent:-0.793cm; } .P29 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:100%; text-indent:0cm; } .P3 { writing-mode:lr-tb; } .P30 { margin-left:2.063cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:-0.793cm; } .P31 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P4 { margin-left:0cm; margin-right:0cm; text-indent:0cm; writing-mode:lr-tb; } .P5 { margin-left:0cm; margin-right:0cm; text-align:center ! important; text-indent:0cm; writing-mode:lr-tb; } .P6 { margin-left:0cm; margin-right:0cm; text-align:right ! important; text-indent:0cm; } .P7 { margin-left:0cm; margin-right:0cm; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .P8 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P9 { margin-left:0cm; margin-right:0cm; margin-top:0.529cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .T10 { font-size:24pt; text-shadow:1pt 1pt; } .T11 { font-size:40pt; text-shadow:1pt 1pt; } .T12 { font-size:28pt; text-shadow:1pt 1pt; } .T13 { color:#ff3300; text-shadow:1pt 1pt; } .T14 { text-shadow:1pt 1pt; } .T15 { font-style:italic; text-shadow:1pt 1pt; } .T16 { color:#ff3300; font-size:36pt; text-shadow:1pt 1pt; } .T17 { color:#000000; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T18 { color:#ffffff; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T19 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T2 { color:#ffffff; font-size:14pt; text-shadow:1pt 1pt; } .T20 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T21 { color:#000000; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T22 { color:#ffffff; font-size:28pt; text-shadow:1pt 1pt; } .T23 { text-shadow:1pt 1pt; text-decoration:underline; } .T24 { font-size:36pt; text-shadow:1pt 1pt; } .T25 { color:#e5ffff; text-shadow:1pt 1pt; } .T26 { font-size:24pt; text-shadow:1pt 1pt; } .T27 { font-size:24pt; text-shadow:1pt 1pt; } .T28 { font-size:24pt; text-shadow:1pt 1pt; font-weight:bold; } .T29 { font-size:20pt; text-shadow:1pt 1pt; } .T3 { color:#ccecff; font-size:54pt; text-shadow:1pt 1pt; } .T30 { font-size:18pt; text-shadow:1pt 1pt; } .T31 { font-size:24pt; font-style:italic; text-shadow:1pt 1pt; } .T32 { font-size:36pt; text-shadow:1pt 1pt; font-weight:bold; } .T33 { color:#ffcc00; font-size:28pt; text-shadow:1pt 1pt; font-weight:bold; } .T34 { color:#ffcc00; font-size:24pt; text-shadow:1pt 1pt; } .T35 { font-size:18pt; font-style:italic; text-shadow:1pt 1pt; } .T36 { font-size:24pt; font-style:italic; text-shadow:1pt 1pt; font-weight:bold; } .T37 { color:#ffcc00; font-size:28pt; font-style:italic; text-shadow:1pt 1pt; font-weight:bold; } .T38 { font-size:20pt; font-style:italic; text-shadow:1pt 1pt; } .T4 { text-shadow:1pt 1pt; } .T5 { font-size:24pt; text-shadow:1pt 1pt; } .T6 { font-size:24pt; text-shadow:1pt 1pt; } .T7 { font-size:20pt; text-shadow:1pt 1pt; } .T8 { font-size:28pt; text-shadow:1pt 1pt; } .T9 { font-size:36pt; text-shadow:1pt 1pt; } <!-- ODF styles with no properties representable as CSS --> .dp1 .dp2 .dp3 .dp4 .dp5 .T1 { } Asaldura metabolikoak DiabeteaIntsulinaren gabeziak jariopenean edo eraginean → Hipergluzemia Hipergluzemia kronikoa Erretinopatiak Neuropatiak Giltzurrunen asaldurak Bihotzaren asaldurak Odol-hodien asaldurak Motak Diabete mellitus 1 Diabete mellitus 2 DiabeteaDiabete mellitus 1 Intsulinaren jariopenaren erabateko gabezia Diabete mellitus 2 Intsulinarekiko erresistentzia Jariaketaren erantzun desegokia Sintomatologia Poliuria Polidipsia Gluzemia basala > 126mg/dl Tratamenduaren helburuakGluzemiaren maila jaistea balio normalaruntz (100-120 mg/dl) Desoreka akutuak, zetoazidosia edo sindrome hiperosmolarra ekiditea Sintoma nagusiak murriztu (poliuria, polidipsia, astenia...) Erlazionatutako patologien agerpena edo garapenerako arriskua murriztu Hipogluzemiak ekiditea Pazienteen profil lipidikoa hobetzea Hilkortasuna jaistea TratamenduaHezkuntza diabetologikoa (autokontrola, sintomak...) Elikadurarako gomendioak (glukosa, lipidoak...) Ariketa fisikoa Farmakoak Terapia genikoa?? Tratamendu farmakologikoaIntsulinak Ultralaburra, azkarra, erdikoa, luzea Analogoak (lispro) Intsulina azkarrak vs giza intsulinaAbantailakBarne intsulinaren antzeko profila jan ondoren Janondoko kontrol gluzemiko hobeagoa HbA ↓ handiagoa ↓ Gaueko hipogluzemiak Bizi kalitate hobeagoa DesabantailakGarestiagoak Dosia igotzea beharrezkoa izan daiteke Epe luzeko seguritatea eta onura zehazteke Tratamendu farmakologikoaAho-bidetiko hipogluzemiatzaileak Intsulinaren jariopena bultzatzen dute •Sulfonilureak •Meglitinidak Erresistentzia murrizten dute •Biguanidak (metformina) •Tiazolidinadionak (glitazonak) Karbohidratoen xurgapena murrizten dute •Hesteetako alfa-glukosidasen inhibitzaileak Aho-bidetiko hipogluzemiatzaileak OSTEOPOROSIA Osteoporosia Hezur-masa + hezur ehunaren mikroegituraren kaltea  Hezurraren hauskortasuna +  hausturarako arriskua Diagnostiko → hezurren densitometria Oinarrizko osteoporosia I motakoa edo menopausiaondokoa II motakoa edo zahartzarokoa Gizonak zein emakumeak >70 urte Ondoriozko osteoporosia Farmakoek eragindakoa (glukokortikoide sistemikoak) Hipogonadismoa Gaixotasun zeliakoa Arrisku faktoreakTraumatismo arinak eragindako aurreko hausturak Farmakoen erabilpen kronikoa Kortikoideak, antiepileptikoak, litio, heparina Menopausia Historia familiarra, menopausia goiztiarra, amenorrea, argaltasuna, tabakismo... Gaixotasun osteopenizatzaileak Alkoholismoa, Crohn, nefropatía kronikoa, Cushing, artritis erreumatoidea... Nor tratatu behar dugu???Osteoporosis eta aurreko orno-haustura duten pazienteak Osteoporosis eta hausturarako arrisku gehigarriak dituzten pazienteak Adina Erortzeko arrisku handia Lehenago traumatismo arinak eragindako hausturak Osteoporosis edo traumatismo arinak eragindako hausturen aurrekari familiarrak Tratamendu ez-farmakologikoak Alkohola eta tabakoa ekiditu (hezur-masaren galera +%0,2 urtero) Ariketa fisikoa Elikadura (kaltzioa, D bitamina) Aldakaren babesleak Erorketak prebenitzea Entzumen edo ikusmenaren asaldurak konpondu Oreka edo ibiltzearen asaldurak eragiten dituzten gaixotasunak tratatu Bizkortasuna edo arreta murrizten duten farmakoak ekiditu Jarreragatiko hipotentsioa ekiditu Oinetakoak eta ingurunea zaindu Tratamendu farmakologikoBifosfonatoak (alendronato, risedronato, etidronato, ibandronato) Lehen aukerako farmakoak Hezur-birxurgapena inhibitzen dute %30-60 Aldakaren hausturarako arriskua %41-55 orno-hausturen intzidentzia Kaltzitonina Osteoklastoen eragina inhibitzen du Eragin analgesiko zentrala %33 orno-hausturarako arriskua Ez zuen murriztu aldakaren hausturarako arriskua Tratamendu farmakologikoRaloxifeno Estrogenoentzako hartzaileen modulatzaile selektiboa %30-50 orno-hausturarako arriskua Ez zuen murriztu aldakaren hausturarako arriskua Hiru aldiz arazo tronboenboliko gehiago Kaltzio + D bitamina %27 Aldakaren hausturarako arriskua %50 haustura ez-bertebralen arriskua Tratamendu farmakologikoTeriparatida Giza hormona paratiroidearen zati aktiboaren analogo errekonbinantea  orno-hausturen intzidentzia Ez zuen murriztu aldakaren hausturarako arriskua Osteosarkoma metastatiko dosimenpekorra arratoietan Azalpeko bidez, hozkailuan gorde behar Oso garestia Tratamendu farmakologikoOrdezko terapia hormonala  Aldakaren hausturarako arriskua arazo koronarioak, iktusa, bularreko minbizia, biriketako enbolismoaren arriskua Ez dago inolako arrazoirik osteoporosiaren prebentzioan zein tratamenduan erabiltzeko Bestelakoak (Fluoruroak, ipriflabona, soja, tiazidak, tibolona) Ez dute murrizten hausturarako arriskua Tratamendu farmakologiko Tratamendu farmakologiko
